Idiopathic Pulmonary Fibrosis (IPF) clinical trials
44 active trials name this condition (recorded in the registry as “Idiopathic Pulmonary Fibrosis”) . Describe your situation to see which ones look like a fit.
By location
- H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
- A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
- WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
- A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
- Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- NAL ER IPF Respiratory Function and Safety Study
- Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
- A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis
- Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
- Dose-Escalation Study of Artesunate Patients With IPF
- Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
- An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL)
- Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
- RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
- Development of FAPI PET as a Non-invasive Biomarker of Pulmonary Fibrogenesis
- Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
- Pulmonary Hypertension SOLAR
- Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets
- Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)
- Single Time Point Prediction as Earlier Diagnosis of Progressive Pulmonary Fibrosis
- A Phase IIb Study to Evaluate AZD8965 in Participants With IPF.
- The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis
- Mechanisms of Familial Pulmonary Fibrosis
- The Genetics of Pulmonary Fibrosis
- The Role of Laryngopharyngeal Reflux in IPF
- Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
- Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)
- Pulmonary Fibrosis Foundation Community Registry
- A Study of the Natural Progression of Interstitial Lung Disease (ILD)
- LAM-001 for the Treatment of Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
- Interstitial Lung Disease Research Unit Biobank
- Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
- Hyperpolarized Xenon-129 MRI in Idiopathic Pulmonary Fibrosis
- Phase 2 Clinical Trial of MNKD-201 (Nintedanib Dry Powder Inhalation) in Patients With Idiopathic Pulmonary Fibrosis
- Autoantibody Reduction Therapy for Progressive Idiopathic Pulmonary Fibrosis
- Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis
- Metformin to Attenuate Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis
- A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension
- Remote Evaluation and Surveillance of Patients With Interstitial Lung Disease: Transforming ILD Care Delivery With Remote Monitoring
- Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
- University of Virginia Natural History Study
- Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With IPF
- A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
- Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Idiopathic Pulmonary Fibrosis” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.